- 11012台北市信義區基隆路一段333號18樓1806室
- Taiwania Capital Management USA, Inc 3945 Freedom Circle, Suite 760, Santa Clara, CA 95054
Portfolio
Updated：
Ambiq Micro (Fund I)
The world-leading design in energy-efficient semiconductor design, redefining "ultra-low-power" for wireless sensors, IoT and voicecontrolled products.
AnnJI Pharma (Fund II)
Translate and develop first-in-class and best-in-class small molecules. Taiwan’s leading new drug developers in dermatology and neurology.
AEye (Fund I)
AEye is an artificial perception pioneer and creator of iDAR™, a new form of intelligent data collection, in order to deliver military-grade performance in autonomous vehicles.
Arris Composites (Fund I)
Arris develops continuous carbon fiber composites that can be combined with other materials in a fast process that combines 3D printing and traditional high-volume manufacturing.
C4 Therapeutics (Fund II)
The company develops synthetic chemical compounds to bind with disease-causing proteins and flag them as cellular trash to get rid of them, enabling patients to begin treatment more quickly and result in a higher likelihood of successful treatment.
DSP Concepts (Fund I)
A leading provider of audio development tools and audio IP for creators of audio-enabled products and are used by major automotive and consumer products.
EirGenix (Fund II)
The company operates a CDMO unit to provide biopharmaceutical contract development and manufacturing services, and a product unit developing affordable biosimilars to the benefits of global patients.
ELIXIRON (Fund II)
Founded in 2017, ELIXIRON is dedicated to offering unique immunotherapeutic solutions for patients with presently untreatable cancers and chronic hepatitis B.
FRACTYL (Fund II)
The company develops a device-based clinical platform designed to address insulin resistance and restore metabolic health.
Frequency Therapeutics (Fund II)
A clinical-stage biotechnology company focused on harnessing the body’s innate biology to repair or reverse damage caused by a broad range of degenerative diseases.
Handa Pharma (Fund II)
A specialty pharmaceutical company focused on the development of niche drug including 505(b)(2)new drug and high barrier/patentable generics development.
LANDING AI (Fund I)
Landing AI founded in 2017 in Palo Alto, California. The company provides deployment-ready AI solutions, enterprise-wide transformation programs, and technology platforms for customers worldwide.
LIGHT FIELD LAB (Fund I)
Real holograms, no headgear, a holographic display startup founded in 2017. The Company builds and markets the world’s most innovative holographic ecosystem.
MedicusTeck (Fund I)
With IoT design concept, connecting medicine, technology and data analysis, providing artificial intelligence solution to improve patient safety and reduce medical costs.
Mechavision (Fund I)
A spin-off from Industrial Technology Research Institute, focusing on robot tactile sensor related IoT and intelligent manufacturing applications.
Metanoia Communications Inc. (Fund I)
Metanoia is an IC Design House developing modem SoC for fixed-line CO/CPE and plans to enter 5G small cell market. Product lines include G.Fast/XDSL modem IC
OCULii (Fund I)
Oculii is an advanced radar sensor developer specializing in 4D radar design and fusion and is working with the leaders in Self Driving Vehicles, Robotics, and Drones.
Pavilion Data Systems (Fund I)
With maximum performance density and an OpenChoice of NVMe SSDs and NVMe-oF topologies, Pavilion has a proven solution for organizations at a lower price, technical flexibility, and better storage utilization.
PharmaEssentia (Fund II)
Developing global rights of drug candidates in a wide range of indications with the core technology of PEGylation to tackle unmet medical needs and improve patients’ life.
Point Robotics MedTec (Fund II)
Point Robotics MedTech is a spinal surgical robot company that is committed to making spinal surgeries safer for the patients and the doctors. The goal is to be one of the leaders in medical robots globally.
Regenacy Pharmaceuticals (Fund II)
A clinical-stage biopharmaceutical company regenerating biological function by protein acetylation for the treatment of diabetic and other peripheral neuropathies and other chronic conditions.
TRICORNTECH (Fund I)
With a complete own R&D team and customized solutions, TRICORNTECH’s MiTAP VOC analyzer is the world’s first online monitoring system capable of providing laboratory-grade performance (0.1 ppb) out in the field.
Viracta (Fund II)
A clinical-stage drug development company focused on advancing new therapies to address a broad range of cancers and virus-associated diseases.
XGene (Fund II)
A clinical-stage pharmaceutical company focusing on developing small molecule therapeutics to treat pain, infectious diseases and cancers.